Literature DB >> 22155094

Gender differences in the IL6 -174G>C and ESR2 1730G>A polymorphisms and the risk of Parkinson's disease.

M San Luciano1, L Ozelius, R B Lipton, D Raymond, S B Bressman, R Saunders-Pullman.   

Abstract

The -174G>C (rs1800795) single nucleotide polymorphism (SNP) in the promoter of the interleukin-6 (IL6) gene and the 1730G>A (rs4986938) SNP in the estrogen receptor beta (ESR2) may influence the risk of Parkinson's disease (PD). We investigated these SNPs in 380 unrelated US Caucasian PD cases and 522 controls, including 452 individuals of Ashkenazi Jewish (AJ) origin (260 PD, 192 controls). The G allele of the -174G>C SNP was more common in AJ PD cases (p=0.033) as well as in Non-Jewish (NJ) men with PD (p=0.022). The GG genotype increased the risk of PD by over two fold in NJ men (OR=2.11, 95%CI: 1.14-3.89, p=0.017), and approached significance in the total AJ group with PD (OR=1.42, 95%CI: 0.97-2.06, p=0.067). The A allele of the ESR2 1730G>A SNP was associated with a decreased risk for PD in AJ women, and in this group, having the AA genotype decreased the risk of PD by half (OR=0.45, 95%CI: 0.22-0.92, p=0.029). Our data supports a role for the IL6 -174G>C G allele in AJ individuals overall. In NJ Caucasians, this role appears to be gender mediated. In both groups, the effect is independent from ESR2 1730G>A. A separate association for the ESR2 1730G>A SNP was found exclusively in women of AJ descent. Other polymorphisms in tight linkage disequilibrium with the SNP differentially influencing expression, ethnic differences in allele distribution, and gender differences in genetic load related to PD, may underlie our findings. Larger studies in diverse populations, including analysis of surrounding regions are recommended.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155094      PMCID: PMC3249002          DOI: 10.1016/j.neulet.2011.11.032

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  42 in total

1.  Repression of interleukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor.

Authors:  P Ray; S K Ghosh; D H Zhang; A Ray
Journal:  FEBS Lett       Date:  1997-06-02       Impact factor: 4.124

2.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

3.  A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease.

Authors:  Z I Alam; S E Daniel; A J Lees; D C Marsden; P Jenner; B Halliwell
Journal:  J Neurochem       Date:  1997-09       Impact factor: 5.372

4.  Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures.

Authors:  T Hama; Y Kushima; M Miyamoto; M Kubota; N Takei; H Hatanaka
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

5.  Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease.

Authors:  T Müller; D Blum-Degen; H Przuntek; W Kuhn
Journal:  Acta Neurol Scand       Date:  1998-08       Impact factor: 3.209

6.  Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6.

Authors:  I L Campbell; C R Abraham; E Masliah; P Kemper; J D Inglis; M B Oldstone; L Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

7.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Authors:  D Fishman; G Faulds; R Jeffery; V Mohamed-Ali; J S Yudkin; S Humphries; P Woo
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

8.  17 beta-Estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism.

Authors:  S T Pottratz; T Bellido; H Mocharla; D Crabb; S C Manolagas
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

9.  Association between the estrogen receptor beta gene and age of onset of Parkinson's disease.

Authors:  L Westberg; A Håkansson; J Melke; H Niazi Shahabi; S Nilsson; S Buervenich; A Carmine; J Ahlberg; M B Grundell; B Schulhof; K Klingborg; B Holmberg; O Sydow; L Olson; E B Johnels; E Eriksson; H Nissbrandt
Journal:  Psychoneuroendocrinology       Date:  2004-09       Impact factor: 4.905

10.  Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains.

Authors:  P L McGeer; S Itagaki; B E Boyes; E G McGeer
Journal:  Neurology       Date:  1988-08       Impact factor: 9.910

View more
  5 in total

Review 1.  The relevance of gender in Parkinson's disease: a review.

Authors:  Marina Picillo; Alessandra Nicoletti; Vincenza Fetoni; Barbara Garavaglia; Paolo Barone; Maria Teresa Pellecchia
Journal:  J Neurol       Date:  2017-01-04       Impact factor: 4.849

2.  Genetic polymorphisms in VDR, ESR1 and ESR2 genes may contribute to susceptibility to Parkinson's disease: a meta-analysis.

Authors:  Zhan Gao; Hong-Juan Fu; Ju-Jun Xue; Zhi-Xuan Wu; Li-Bo Zhao
Journal:  Mol Biol Rep       Date:  2014-03-05       Impact factor: 2.316

Review 3.  Gender Differences and Quality of Life in Parkinson's Disease.

Authors:  Pietro Crispino; Miriam Gino; Elena Barbagelata; Tiziana Ciarambino; Cecilia Politi; Immacolata Ambrosino; Rosalia Ragusa; Marina Marranzano; Antonio Biondi; Marco Vacante
Journal:  Int J Environ Res Public Health       Date:  2020-12-29       Impact factor: 3.390

4.  Assessment of the Telomere Length and Its Effect on the Symptomatology of Parkinson's Disease.

Authors:  Tina Levstek; Sara Redenšek; Maja Trošt; Vita Dolžan; Katarina Trebušak Podkrajšek
Journal:  Antioxidants (Basel)       Date:  2021-01-19

5.  Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease.

Authors:  Marta San Luciano; Cuiling Wang; Roberto A Ortega; Nir Giladi; Karen Marder; Susan Bressman; Rachel Saunders-Pullman
Journal:  Ann Clin Transl Neurol       Date:  2017-10-19       Impact factor: 4.511

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.